Medy-Tox Inc. (KOSDAQ:086900)

South Korea flag South Korea · Delayed Price · Currency is KRW
101,900
-2,600 (-2.49%)
Apr 10, 2026, 3:30 PM KST
Market Cap685.02B -21.3%
Revenue (ttm)247.29B +8.2%
Net Income16.59B -2.1%
EPS2,371.00 -0.3%
Shares Out6.56M
PE Ratio44.07
Forward PE27.21
Dividend1,200.00 (1.18%)
Ex-Dividend DateSep 29, 2025
Volume37,709
Average Volume43,251
Open102,900
Previous Close104,500
Day's Range101,300 - 103,500
52-Week Range96,400 - 182,700
Beta0.49
RSI41.12
Earnings DateMay 15, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 718
Stock Exchange KOSDAQ
Ticker Symbol 086900
Full Company Profile

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 16.59 billion, a decrease of -2.13%.

Financial Statements